For a better experience, click the Compatibility Mode icon above to turn off Compatibility Mode, which is only for viewing older websites.

Drexel Medicine Diagnostics Toxicology Services
Ketamine, Urine, Quantitative

OVERVIEW

Purpose: Detection and quantification of ketamine in urine.

CLINICAL INFORMATION

Ketamine, renowned for its potent attributes as a dissociative anesthetic and hallucinogen, has been used as a veterinary tranquilizer. Esketamine, available as Spravato®, has obtained FDA approval as a nasal spray for treatment-resistant depression in individuals afflicted by major depressive disorder (MDD), particularly those contending with suicidal ideation or actions. The proclivity for misuse and abuse of ketamine originates from its alluring potential to induce detachment and elicit hallucinatory effects, underscoring the importance of vigilant monitoring. The test is a definitive assay using liquid chromatography mass spectroscopy (LC/MS/MS) methodology.

SPECIMEN COLLECTION

Specimen Type: Random Urine
Preferred Collection Container: Non-sterile specimen container
Specimen Required: 3 mL urine; minimum 1 mL

TEST DETAILS

Methodology: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Compliance Category: Laboratory Developed Test (LDT)
This test was developed and assessed by DMD in compliance with CLIA requirements for its analytical performance characteristics and clinical application. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Reference Interval: Negative
Drug/Metabolite Tested:
Drug/Metabolite Cutoff concentration 500 ng/mL
Ketamine 50 ng/mL
Norketamine 50 ng/mL
CPT code(s): 80357
Turnaround Time: 90% < 48 hours, 50% < 24 hours

SPECIMEN PROCESSING

Transport Temperature: Refrigerated (preferred) or room temperature overnight shipping.
Specimen Stability: 3 days at room temperature and 14 days at refrigerated and frozen temperatures (to be further confirmed with our validation).
Rejection Criteria: Stability limits exceeded.

Director: Cheryl Hanau, MD; Donald Hall Jr., PhD; Garth Ehrlich, PhD; Yinghua Qiu, PhD, DABCC

Review Date: 08/28/2023

Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.


The information on these pages is provided for general information only and should not be used for diagnosis or treatment, or as a substitute for consultation with a physician or health care professional. If you have specific questions or concerns about your health, you should consult your health care professional.

 
 Back to Top